Cellectar Biosciences, Inc. (CLRB) Financial Statements (2026 and earlier)

Company Profile

Business Address 100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,196,03323,288,6079,564,98819,866,35835,703,97557,165,377
Cash and cash equivalent13,196,03323,288,6079,564,98819,866,35835,703,97557,165,377
Other undisclosed current assets842,432961,665888,225663,243867,485774,432
Total current assets:14,038,46524,250,27210,453,21320,529,60136,571,46057,939,809
Noncurrent Assets
Operating lease, right-of-use asset360,671436,874502,283560,334 282,365
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization549,405757,1211,090,304418,641344,491355,982
Long-term investments and receivables   23,56675,00075,00075,000
Long-term investments   23,56675,00075,00075,000
Other noncurrent assets29,78029,7806,2146,2146,2146,214
Other undisclosed noncurrent assets     204,644 
Total noncurrent assets:939,8561,223,7751,622,3671,060,189630,349719,561
TOTAL ASSETS:14,978,32125,474,04712,075,58021,589,79037,201,80958,659,370
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:4,423,5487,585,3409,178,6455,478,4433,854,9143,443,197
Employee-related liabilities✕✕✕✕✕504,000850,000
Accounts payable 1,441,0004,105,0005,620,0002,558,0001,415,0001,429,000
Accrued liabilities 1,904,0002,141,0002,307,0001,283,00055,000377,000
Other undisclosed accounts payable and accrued liabilities1,078,5481,339,3401,251,6451,637,4431,880,914787,197
Derivative instruments and hedges, liabilities226,0001,718,0003,700,000   
Other undisclosed current liabilities 100,18984,41758,97950,847135,449119,904
Total current liabilities:4,749,7379,387,75712,937,6245,529,2903,990,3633,563,101
Noncurrent Liabilities
Long-term debt and lease obligation:     166,292301,740
Liabilities, other than long-term debt309,397409,586494,003552,981  
Operating lease, liability309,397409,586494,003552,981166,292301,740
Other undisclosed noncurrent liabilities     (166,292)(301,740)
Total noncurrent liabilities:309,397409,586494,003552,981166,292301,740
Total liabilities:5,059,1349,797,34313,431,6276,082,2714,156,6553,864,841
Equity
Equity, attributable to parent, including:8,537,16414,294,681(1,356,047)15,507,51933,045,15454,794,529
Preferred stock   1,382,023  
Common stock4246120794611454
Additional paid in capital277,149,844261,115,905210,066,630193,624,445182,560,309161,533,653
Accumulated deficit(269,133,500)(247,342,463)(217,482,539)(179,499,043) (126,775,427)
Other undisclosed equity, attributable to parent 520,778520,7786,059,655 (149,515,766)20,035,849
Other undisclosed equity1,382,0231,382,023    
Total equity:9,919,18715,676,704(1,356,047)15,507,51933,045,15454,794,529
TOTAL LIABILITIES AND EQUITY:14,978,32125,474,04712,075,58021,589,79037,201,80958,659,370

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(22,979,844)(51,777,698)(38,960,643)(28,813,773)(24,131,280)(15,290,349)
Operating loss:(22,979,844)(51,777,698)(38,960,643)(28,813,773)(24,131,280)(15,290,349)
Nonoperating income1,188,8077,262,252917,147152,5198,918196,177
Investment income, nonoperating     6,634 
Interest and debt expense      185,280
Loss from continuing operations before income taxes:(21,791,037)(44,515,446)(38,043,496)(28,661,254)(24,122,362)(14,908,892)
Income tax expense (benefit) 6,854,000(66,000)60,00060,000  
Other undisclosed income from continuing operations      
Loss from continuing operations:(14,937,037)(44,581,446)(37,983,496)(28,601,254)(24,122,362)(14,908,892)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(24,122,362)(14,908,892)
Net loss:(14,937,037)(44,581,446)(37,983,496)(28,601,254)(24,122,362)(14,908,892)
Other undisclosed net loss attributable to parent(6,854,000)    (185,280)
Net loss available to common stockholders, basic:(21,791,037)(44,581,446)(37,983,496)(28,601,254)(24,122,362)(15,094,172)
Dilutive securities, effect on basic earnings per share  (7,283,786)    
Net loss available to common stockholders, diluted:(21,791,037)(51,865,232)(37,983,496)(28,601,254)(24,122,362)(15,094,172)

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(14,937,037)(44,581,446)(37,983,496)(28,601,254)(24,122,362)(14,908,892)
Comprehensive loss, net of tax, attributable to parent:(14,937,037)(44,581,446)(37,983,496)(28,601,254)(24,122,362)(14,908,892)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: